Cytori Therapeutics Reports Preliminary Preclinical Data Supporting Use Of Cytori Cell Therapy For Both The Prevention And Treatment Of Hypertrophic Scars

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) today presented preclinical data at the Annual Meeting of the American Burn Association (ABA) in Las Vegas showing the potential of Cytori’s DCCT-10 cell therapy for hypertrophic scarring (HTS), a common consequence of burn injury.

“These data suggest the potential for DCCT-10 therapy to mitigate scarring following deep partial thickness skin injury”

In this research Cytori scientists developed and applied a preclinical model of HTS in two treatment studies. In the first, DCCT-10 was applied to deep partial thickness skin wounds immediately following injury. Wounds were then followed for six months to allow for the development of HTS. Results demonstrate that delivery of DCCT-10 immediately after injury led to a 60% increase in the number of anchoring structures called ‘rete ridges’ or ‘rete pegs’ within the skin (p<0.001) of treated wounds compared to the control. Rete ridges, which help to anchor the epidermis to the dermis, are absent or substantially reduced in scar tissue which is one reason that scar epidermis is often more fragile than that of normal skin. The six month data also showed a 15% decrease in skin hardness in DCCT-10-treated wounds (p=0.067). The second study, which is still ongoing, used the same model to assess use of DCCT-10 delivered six months after deep partial thickness injury in which a hypertrophic scar had already formed. Preliminary data from this study presented today show a 20-40% decrease in skin hardness at 1 and 2 months post-treatment.

While DDC-10 treatment appeared to modulate skin pliability and hardness in both studies, no effect was observed on scar pigmentation or erythema.

“These data suggest the potential for DCCT-10 therapy to mitigate scarring following deep partial thickness skin injury,” said Dr. Marc Hedrick, President and CEO of Cytori. “When combined with earlier work on the use of DCCT-10 following thermal burn injury, these findings suggest a potentially broad utility for this product in burn and wound clinics. We are encouraged by this research and look forward to completing these studies and, in a continuation of our work with BARDA, initiating a clinical trial of DCCT-10 therapy in burn patients within the next year.”

Presentations Details:
Abstract #268
Title: Non-Invasive Objective Characterization of Hypertrophic Scarring in the Female Red Duroc Porcine Model
Presenter: Philippe Foubert
Poster: P-033. Wounds – Translational II
Link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4011&sKey=28522021-6e57-4389-8e9c-d61d76624b99&cKey=5d18603d-f1a5-4b43-923a-ea10fdf50cc7&mKey=14aa6ca4-b9b4-4ecf-b27c-dd7c3170e3c9

Abstracts are currently available on the American Burn Association website at http://www.ameriburn.org/48thAnnualMeeting.php

This research was funded by contract HHS0100201200008C from the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services.

About Cytori Therapeutics, Inc.

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary solutions.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts, including statements regarding our expectation that the research and development activities, and the data to be presented at ABA will lead to FDA IDE approval and unlocking of the next BARDA contract milestone are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical, pre-clinical and regulatory uncertainties, risks in the collection and results of data, uncertainty associated with any future approvals by the FDA, dependence on third party performance, the right of the Federal Government to cut or terminate further support of the thermal burn injury program in its sole discretion, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.

Cytori Therapeutics, Inc.
Tiago Girao, +1 858-458-0900
ir@cytori.com

Back to news